2-Aminoindane (2-AI) is a stimulant of the 2-aminoindane family which has been sold as a designer drug.
2-AI is a monoamine releasing agent acting as a selective substrate for NET and DAT. It partially substitutes for amphetamine in rodent drug discrimination tests.
The chemical synthesis of 2-aminoindane was reported. For example, a 79% yield was reported from indene and ammonia precursors. The older method uses 1-indanone as the starting material.
2-AI is a rigid analogue of amphetamine and has similar effects in rodents. Other related homologues and rigid analogues of amphetamine include 2-aminotetralin (2-AT), 2-amino-1,2-dihydronapthalene (2-ADN), 1-naphthylaminopropane (1-NAP), 2-naphthylaminopropane (2-NAP), 1-phenylpiperazine (1-PP), , and .
A number of derivatives of 2-aminoindane, also known as substituted 2-aminoindanes, are known, including 5-IAI, aprindine, BFAI, BFMAI, DHAI, DOM-AI ETAI, indantadol, MDAI, MEAI (5-MeO-2-AI), MDMAI, MMAI, NM-2-AI, PNU-99,194, Pyr-AI, and TAI, among others. Rexaceract (c.f. GT-02287) contains the 2-AI pharmacophore.
As of October 2015 2-AI is a controlled substance in China.
Scheduled in the "Government decree on psychoactive substances banned from the consumer market".
Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.
2-Aminoindane is not scheduled at the federal level in the United States, but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.